Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma

Publisher: Karger

E-ISSN: 1421-9794|62|1|19-22

ISSN: 0009-3157

Source: Chemotherapy, Vol.62, Iss.1, 2016-05, pp. : 19-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content